Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation ndi matenda akhungu omwe amadziwika ndi kuchuluka kwa pigment pakhungu pambuyo potupa khungu. Postinflammatory hyperpigmentation imatha kuyambitsidwa ndi kukhala padzuwa kwanthawi yayitali, kutupa, kapena kuvulala kwina kwapakhungu, kuphatikiza zokhudzana ndi ziphuphu. Anthu omwe ali ndi khungu lakuda nthawi zambiri amakhala ndi vuto la hyperpigmentation chifukwa chokhala ndi dzuwa kwambiri.
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
References
Postinflammatory hyperpigmentation (PIH) ndizovuta zapakhungu zomwe zimachitika pakatupa kapena kuvulala. Zimakonda kukhala nthawi yayitali ndipo zimakhala zoipitsitsa kwa anthu omwe ali ndi khungu lakuda (Fitzpatrick skin types III–VI) . Ngakhale kuti nthawi zambiri zimakhala bwino paokha, izi zingatenge nthawi, choncho chithandizo nthawi zambiri chimafunika kwa nthawi yaitali. Kuphatikiza mankhwala osiyanasiyana kumagwira ntchito bwino.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ndi njira yodziwika bwino yotupa pakhungu. Zimakonda kukhudza anthu akhungu lakuda kwambiri komanso pafupipafupi. Kafukufuku akuwonetsa kuti nkhani ngati postinflammatory hyperpigmentation ndi zina mwa zifukwa zazikulu zomwe anthu omwe ali ndi khungu lakuda amafuna chisamaliro cha dermatological. Kuchiza msanga ndikofunikira kuti muthetse postinflammatory hyperpigmentation ndipo nthawi zambiri zimayamba ndikuwongolera momwe kutupa kumayambira. Njira yoyamba ya chithandizo nthawi zambiri imaphatikizapo kugwiritsa ntchito mankhwala apakhungu omwe amawunikira khungu limodzi ndi zoteteza ku dzuwa. Othandizira awa, monga hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , amatha kuchepetsa mtundu wa pigmentation kwambiri. Kuphatikiza apo, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy # amagwiritsidwanso ntchito ngati zochotsera utoto, ndi mankhwala atsopano akutuluka. Ngakhale mankhwala apakhungu nthawi zambiri amakhala othandiza pa hyperpigmentation yapamwamba, njira (laser, chemical peel) zitha kukhala zofunikira pamilandu yamakani. Ndikofunika kusamala ndi mankhwalawa kuti mupewe kukwiya komanso kuwonjezereka kwa postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
